Mapping the 7-step credibility assessment to agentic AI in GMP manufacturing
In January 2025, FDA published its first draft guidance on the use of artificial intelligence in drug and biological product development. At its centre is a 7-step credibility assessment framework — a structured, risk-based process that every AI model supporting regulatory decisions will need to satisfy.
The guidance covers the full product lifecycle: nonclinical, clinical, postmarketing, and manufacturing. That last word matters. For the first time, FDA has laid out a clear expectation for how AI systems operating inside GMP manufacturing environments should demonstrate credibility. Not just accuracy. Not just validation. Credibility — defined as a structured body of evidence that the model does what it claims, in the specific context where it’s deployed.
Most pharmaceutical manufacturers deploying AI today have no structured approach for meeting this framework. The gap is not in the models themselves. It’s in the architecture underneath them.
FDA’s credibility framework doesn’t ask “is your AI accurate?” It asks “can you prove your AI is credible for this specific use, at this risk level, with this data, in this environment?” The answer depends entirely on how your AI system was architected.
FDA’s credibility framework did not emerge in isolation. It sits within a broader regulatory acceleration that includes the FRAME Initiative (which names AI as one of four priority manufacturing technologies), the FDA-EMA joint guiding principles for AI across the medicines lifecycle, and the White House AI Action Plan that explicitly references pharmaceutical manufacturing systems as critical AI-enabled technology.
For quality and manufacturing leaders evaluating AI investments, the question is no longer whether regulation is coming. It’s whether your current AI architecture can withstand the scrutiny that’s already been defined.
75%
Of pharmaceutical companies have made AI a strategic priority as of 2025
29%
Of pharma leaders report seeing actual results from AI in manufacturing and supply chain
68%
Of pharma leaders say poor data quality and governance is the primary reason AI initiatives fail
The gap between strategic intent and manufacturing results is striking. Three out of four pharma companies call AI a priority, but fewer than one in three are seeing results on the shop floor. The FDA’s framework helps explain why: most AI deployments in manufacturing were never designed with regulatory credibility in mind. They were designed to demonstrate a capability, not to satisfy a structured evidentiary standard.
The framework is not a checklist. It’s a sequential process where each step builds on the previous one, and the rigour required at each step scales with the assessed risk level. Higher-risk AI applications — where the model has significant influence on decisions with serious consequences — demand more comprehensive evidence.
Here’s what each step requires, and where most pharmaceutical manufacturing AI systems break down.
FDA requires a precise statement of the regulatory question the AI model addresses. Not “we use AI for deviation detection” but “the model identifies out-of-specification batch parameters that may indicate a deviation requiring investigation under 21 CFR 211.192.”
This sounds simple. In practice, it requires that the AI system’s purpose is architecturally scoped — that the system knows exactly what question it’s answering and can articulate the boundary between its output and the human decision that follows. Point solutions bolted onto existing workflows often can’t do this cleanly because the question of interest spans multiple disconnected systems.
The context of use (COU) specifies what will be modelled, what data sources feed the model, how outputs are used, and what human oversight exists. FDA expects a comprehensive COU statement covering inputs, outputs, operational procedures, user interactions, and environmental constraints.
This is where data architecture becomes regulatory architecture. An AI system that pulls batch data from one system, cleaning records from another, and equipment history from a third has a fragmented COU that’s difficult to define, validate, or defend. A system operating on a unified data model — where batches, deviations, cleaning protocols, and equipment lineage exist in one connected graph — can define its COU precisely because the data boundaries are structural, not integration-dependent.
Risk is evaluated on two axes: model influence (how much the AI output drives the decision) and decision consequence (what happens if the AI is wrong). FDA provides a concrete manufacturing example: an AI system analysing vial fill volumes is medium risk because its output complements existing quality control verification rather than replacing it.
This step rewards architectures that maintain human-in-the-loop by design. Systems where AI agents investigate, recommend, and prepare evidence — but a human reviewer makes the final quality decision — naturally fall into lower risk categories than autonomous decision-making systems. The regulatory incentive is clear: build AI that augments quality professionals, not AI that replaces them.
COU spans multiple disconnected systems. Data provenance is unclear. Input boundaries are defined by integration middleware, not data architecture.
Weeks to document
COU maps directly to the data ontology. Every input, output, and data relationship is structurally defined. Provenance is inherent.
Hours to document
High model influence, limited explainability. Requires extensive validation to justify risk level. Human oversight is procedural, not architectural.
High risk tier
AI investigates and recommends. Human reviews and decides. Model influence is medium by design. Audit trail captures both agent reasoning and human judgement.
Medium risk tier
Data quality depends on integration pipelines. Gaps, latency, and transformation errors are difficult to audit. Fit-for-use assessment requires cross-system validation.
Ongoing reconciliation
Data quality is governed at the ontology level. Completeness, accuracy, and consistency are enforced structurally. Fit-for-use evidence is built into the platform.
Continuous assurance
The plan must cover model description, training procedures, data quality criteria, validation strategy, bias mitigation, and lifecycle maintenance — all scaled to the risk level assessed in Step 3. FDA emphasises early engagement for high-risk models.
For manufacturing AI, this step tests whether the system’s architecture supports systematic credibility assessment or whether each model requires bespoke validation infrastructure. Platforms with a shared data model and consistent agent architecture can develop credibility plans that scale across use cases — deviation detection, batch review, cleaning validation — because the underlying data governance, audit trail, and compliance infrastructure is shared.
Execution requires training, testing on independent datasets, calculating performance metrics, conducting robustness checks, and documenting everything reproducibly. FDA is explicit: all procedures must be documented with comprehensive tracking of data and algorithmic changes.
This is where 21 CFR Part 11 compliance intersects with AI credibility. A system that already maintains complete, tamper-evident audit trails for every data point, every agent action, and every human decision has a structural advantage. The execution evidence doesn’t need to be created retroactively — it’s a byproduct of the platform’s compliance architecture.
FDA requires a formal credibility assessment report that stands as a self-contained document — suitable for regulatory submission and FDA inspection. It must include performance results, deviations from the plan, limitations, and supporting technical materials.
The documentation burden is substantial. But for systems where every agent action is logged, every data transformation is traced, and every decision has a complete audit trail, the report is an assembly exercise, not a reconstruction exercise. The evidence already exists in the system’s operational logs.
The final step evaluates whether the total evidence establishes sufficient credibility. If gaps exist, FDA offers five remedial paths: reduce model influence, increase validation rigour, add risk controls, modify the approach, or re-scope the COU.
Critically, FDA frames this as iterative, not pass/fail. The framework is designed to help manufacturers get to credibility, not to block AI adoption. But the path to adequacy is dramatically shorter when the AI architecture was built with these seven steps in mind from the start.
The 68% of pharma leaders who cite data quality and governance as the primary reason AI initiatives fail are describing an architecture problem, not a data problem. The data exists. The governance doesn’t — because the systems were never designed to provide it.
When AI models pull from MES, LIMS, ERP, and QMS through integration middleware, no single system owns the complete data lineage. FDA's fit-for-use requirement (completeness, accuracy, consistency, representativeness) becomes an integration audit rather than a platform attestation.
Most manufacturing AI systems log predictions but not reasoning. FDA's framework requires documentation of how the model arrived at its output, what data it considered, and how that output was used in decision-making. Without architectural support for agent-level audit trails, this evidence must be reconstructed manually.
Point AI solutions require independent credibility assessment infrastructure for each use case. Deviation detection needs its own validation. Batch review needs another. Cleaning validation needs a third. There is no shared compliance architecture to build on.
FDA requires ongoing monitoring, data drift detection, revalidation triggers, and version control — for every deployed model. Across 10, 30, or 50 manufacturing sites, this becomes operationally unsustainable without a unified platform that centralises model governance.
Organisations evaluating AI platforms for pharmaceutical manufacturing should assess whether the architecture structurally supports FDA’s credibility requirements — not just whether the AI produces useful outputs.
A single data model where batches, deviations, CAPAs, cleaning protocols, equipment, and regulatory signals are structurally connected. This makes context-of-use definition precise and data provenance inherent — satisfying Steps 1, 2, and the fit-for-use requirement.
Every agent observation, investigation, recommendation, and human decision captured in a tamper-evident, time-stamped audit trail with electronic signatures. This provides the documentation infrastructure for Steps 5 and 6 as an operational byproduct, not a compliance exercise.
AI agents that investigate, reason, and recommend — but route final decisions to human reviewers. This structurally reduces model influence (Step 3), keeping risk classification in the medium tier where validation requirements are proportionate.
A common compliance architecture that supports credibility assessment for deviation detection, batch review, cleaning validation, and regulatory intelligence through a single governance framework — reducing the per-model overhead that makes Step 4 planning unsustainable at scale.
Centralised lifecycle management with performance monitoring, data drift detection, revalidation triggers, and version control operating across the full facility network. This is the infrastructure for Step 7's ongoing adequacy determination — applied at enterprise scale.
The organisations that build their manufacturing AI on architectures designed for regulatory credibility will navigate FDA’s framework as an operational process. Those that bolt AI onto fragmented systems will face it as a compliance crisis — one model at a time, one site at a time.
FDA’s 7-step credibility framework is not a barrier to AI adoption in pharmaceutical manufacturing. It’s a specification. It tells you exactly what evidence regulators will expect, how risk determines rigour, and what lifecycle obligations come with deployment.
The manufacturers who treat this framework as a design requirement — building AI architectures where credibility is structural rather than aspirational — will deploy faster, validate more efficiently, and scale across sites with confidence. Those who treat it as a post-deployment compliance exercise will find that retrofitting credibility onto fragmented systems is far more expensive than building it in from the start.
The framework is published. The expectations are clear. The architecture decision is yours.